Predictors of Late Effects in Young AML Survivors Explored
Most common late effects were endocrine, cardiovascular, respiratory; likelihood of late effects up for those who underwent HSCT.
Diagnosis & Disease Information
Ivosidenib Plus Azacitidine Well-Tolerated in Select Patients with Acute Myeloid Leukemia
A phase 1b trial found ivosidenib with azacitidine well-tolerated in patients with AML who are ineligible for intensive chemotherapy.
Relapse Risk Reduced in Acute Myeloid Leukemia With Recombinant Human Granulocyte Colony-Stimulating Factor, Decitabine
Among patients with AML, maintenance therapy with rhG-CSF plus decitabine led to fewer relapses compared with patients who received no treatment after HSCT.
Survival Outcomes in Acute Myeloid Leukemia Associated With Measureable Residual Disease Status
Among patients with acute myeloid leukemia, minimal residual disease-negativity may be linked to improved survival rates.
Unfitness Criteria Predict Early Mortality After Intensive Chemotherapy in Acute Myeloid Leukemia
The Ferrara criteria are widely used to identify patients with AML who are most suitable for intensive chemotherapy, though the accuracy is unknown.
FDA Grants Full Approval to Venclexta for Acute Myeloid Leukemia
The full approval was based on efficacy and safety data from the phase 3 VIALE-A (M15-656) and VIALE-C (M16-043) studies.
Chemotherapy for Relapsed or Refracted Acute Myeloid Leukemia Unresponsive Venetoclax Salvage Therapy
Patients with relapsed/refractory AML who do not respond to venetoclax-based salvage therapy may have a response to intensified chemotherapy.
Factors Associated With Suicide in Leukemia Identified
Risk factors include male sex, older age at diagnosis, White race.
2020 Guidelines on Treating Acute Myeloid Leukemia in Older Adults
Recent guidelines have provided additional information on the treatment, management, and risk-stratifications of acute myeloid leukemia in older patients.
Sorafenib Maintenance Post Transplantation for FLT3-ITD Acute Myeloid Leukemia
Sorafenib maintenance showed positive relapse, survival, and safety outcomes for patients with FLT3-ITD acute myeloid leukemia after transplantation.
- Loading...
Loading...
Loading... 
Loading...